Trial Profile

Phase I trial of vemurafenib and low-dose decitabine in patients with malignant melanoma

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Jul 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Decitabine (Primary) ; Vemurafenib (Primary)
Indications Malignant melanoma
Focus Adverse reactions

Most Recent Events

15 Jul 2015 New trial record
02 Jun 2015 Due to the response rate in patients receiving vemurafenib + decitabine in a phase I/II trial (see trial profile 700233849), this phase I trial is planned to investigate the effect of decitabine given at a low dose for a longer duration to ensure maximal depletion of DNA methyltransferase, according to an ASCO abstract.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com